- Home
- PCSA vs KZIA Comparison
PCSA vs KZIA Comparison
Compare PCSA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- KZIA
- Stock Information
- Founded
- PCSA 2011
- KZIA 1994
- Country
- PCSA United States
- KZIA Australia
- Employees
- PCSA N/A
- KZIA N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PCSA Health Care
- KZIA Health Care
- Exchange
- PCSA Nasdaq
- KZIA Nasdaq
- Market Cap
- PCSA 12.0M
- KZIA 11.7M
- IPO Year
- PCSA N/A
- KZIA 1999
- Fundamental
- Price
- PCSA $0.27
- KZIA $6.20
- Analyst Decision
- PCSA Strong Buy
- KZIA Strong Buy
- Analyst Count
- PCSA 1
- KZIA 3
- Target Price
- PCSA $1.00
- KZIA $16.00
- AVG Volume (30 Days)
- PCSA 4.4M
- KZIA 73.4K
- Earning Date
- PCSA 11-06-2025
- KZIA 12-26-2025
- Dividend Yield
- PCSA N/A
- KZIA N/A
- EPS Growth
- PCSA N/A
- KZIA N/A
- EPS
- PCSA N/A
- KZIA N/A
- Revenue
- PCSA N/A
- KZIA $1,246,312.00
- Revenue This Year
- PCSA N/A
- KZIA N/A
- Revenue Next Year
- PCSA N/A
- KZIA N/A
- P/E Ratio
- PCSA N/A
- KZIA N/A
- Revenue Growth
- PCSA N/A
- KZIA N/A
- 52 Week Low
- PCSA $0.15
- KZIA $2.86
- 52 Week High
- PCSA $1.50
- KZIA $30.05
- Technical
- Relative Strength Index (RSI)
- PCSA 43.44
- KZIA 31.41
- Support Level
- PCSA $0.29
- KZIA $7.18
- Resistance Level
- PCSA $0.35
- KZIA $7.99
- Average True Range (ATR)
- PCSA 0.05
- KZIA 0.49
- MACD
- PCSA -0.01
- KZIA -0.14
- Stochastic Oscillator
- PCSA 3.69
- KZIA 12.33
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.